相关实验视频
Updated: Jan 9, 2026

07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
746
肺栓塞管理的进展:当前的方法和未来的方向
Carlo Banfi1,2, Carolina Montonati3, Alfonso Ielasi4
1Department of Cardiothoracic Surgery, IRCCS Ospedale Galeazzi-Sant'Ambrogio, University of Milan, 20157 Milan, Italy.
Reviews in cardiovascular medicine
|December 8, 2025
概括
肺栓塞 (PE) 具有很高的死亡风险. 由于患者的并发症,目前的治疗往往偏离了指导方针,促使人们探索新型疗法,以更好地管理肺栓塞.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 医学研究 医学研究
背景情况:
- 肺栓塞 (PE) 是心血管死亡的重要原因之一.
- 高30天死亡率与PE相关.
- 对于PE管理的临床实践经常偏离了既定的指导方针.
研究的目的:
- 审查目前肺栓塞的流行病学.
- 概述PE的初步评估和常规治疗策略.
- 探索PE管理的新和新兴的治疗方法.
主要方法:
- 关于当前流行病学的文献综述.
- 对标准护理治疗选择的分析.
- 探索PE的新兴疗法.
主要成果:
- 长期发育仍然是心血管死亡的主要原因.
- 在PE患者的并发症使遵守治疗指南变得复杂.
- 目前正在研究新型疗法以改善PE的治疗结果.
结论:
- 在PE治疗指南和临床实践之间存在差距.
- 患者的并发症是治疗偏差的一个关键因素.
- 新兴疗法可能为肺栓塞提供了改进的治疗策略.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
281
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
281
Pulmonary Embolism III: Nursing Management
325
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
325
Pulmonary Embolism I: Introduction
471
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
471
Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
439
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
439

